Jacobson Mark L. 4

What Happened Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics (AXSM), was granted 8,669 performance stock units (PSUs) on April 21, 2026. The grant is reported as an acquisition (award) with a reported price of $0.00 because these are contingent equity awards (derivative securities), not an open-market purchase or sale. No immediate cash changed hands; PSUs convert to common shares only if specified performance and service conditions are met.

Key Details

• Transaction date: 2026-04-21 (Form 4 filed 2026-04-23).
• Transaction type/code: Award/Grant (A) of 8,669 PSUs; reported price $0.00 (derivative).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1—each PSU represents a contingent right to one share of common stock; F2—PSUs vest upon achievement of sales and commercial launch milestones and are subject to the reporting person's continued service at each vesting date.
• Timeliness: Filed two days after the transaction (within the usual two-business-day Form 4 reporting window).

Context PSUs are performance-based equity awards: they only convert into actual shares if the company meets the stated sales/commercial launch goals and the executive remains employed through vesting dates. Such grants are common as long-term incentive compensation and do not necessarily indicate immediate buying or selling intent in the market.